When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

3. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

4. Fluticasone furoate - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate

   The combination drugs fluticasone furoate/umeclidinium bromide/vilanterol, marketed as Trelegy Ellipta, and fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada, New Zealand) and Relvar Ellipta (EU, UK), [33] [34] [35] are approved for use in the United States for long-term maintenance treatment of airflow obstruction in people ...

5. Dry-powder inhaler - Wikipedia

   en.wikipedia.org/wiki/Dry-powder_inhaler

   Three types of dry powder inhalers: Turbuhaler, Accuhaler and Ellipta devices. A dry-powder inhaler ( DPI ) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma , bronchitis , emphysema and COPD although DPIs (such as inhalable insulin ) have also been ...

6. Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

   www.aol.com/news/glaxo-innoviva-file-approval...

   Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

7. Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma - AOL

   www.aol.com/news/glaxo-innovivas-trelegy-ellipta...

   With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.